Literature DB >> 10537900

On the use of survival analysis techniques to estimate medical care costs.

R D Etzioni1, E J Feuer, S D Sullivan, D Lin, C Hu, S D Ramsey.   

Abstract

Measurement of treatment costs is important in the evaluation of medical interventions. Accurate cost estimation is problematic, when cost records are incomplete. Methods from the survival analysis literature have been proposed for estimating costs using available data. In this article, we clarify assumptions necessary for validity of these techniques. We demonstrate how assumptions needed for valid survival analysis may be violated when these methods are applied to cost estimation. Our observations are confirmed through simulations and empirical data analysis. We conclude that survival analysis approaches are not generally appropriate for the analysis of medical costs and review several valid alternatives.

Mesh:

Year:  1999        PMID: 10537900     DOI: 10.1016/s0167-6296(98)00056-3

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  19 in total

1.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Current Methods for Recurrent Events Data with Dependent Termination: A Bayesian Perspective.

Authors:  Debajyoti Sinha; Tapabrata Maiti; Joseph G Ibrahim; Bichun Ouyang
Journal:  J Am Stat Assoc       Date:  2008-06-01       Impact factor: 5.033

3.  Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients.

Authors:  A D Griffin; A S Perry; D M Fleming
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  China's medical savings accounts: an analysis of the price elasticity of demand for health care.

Authors:  Hao Yu
Journal:  Eur J Health Econ       Date:  2016-09-20

5.  Risk-adjusted capitation rates for children: how useful are the survey-based measures?

Authors:  Hao Yu; Andrew W Dick
Journal:  Health Serv Res       Date:  2010-09-01       Impact factor: 3.402

6.  The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.

Authors:  Jean A McDougall; Aasthaa Bansal; Bernardo H L Goulart; Jeannine S McCune; Andy Karnopp; Catherine Fedorenko; Stuart Greenlee; Adriana Valderrama; Sean D Sullivan; Scott D Ramsey
Journal:  Oncologist       Date:  2016-02-10

Review 7.  Multiple chronic conditions and healthcare costs among adults.

Authors:  Usha Sambamoorthi; Xi Tan; Arijita Deb
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015       Impact factor: 2.217

8.  ESTIMATING MEAN SURVIVAL TIME: WHEN IS IT POSSIBLE?

Authors:  Ying Ding; Bin Nan
Journal:  Scand Stat Theory Appl       Date:  2015-06-01       Impact factor: 1.396

9.  EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT.

Authors:  Elizabeth A Handorf; Justin E Bekelman; Daniel F Heitjan; Nandita Mitra
Journal:  Ann Appl Stat       Date:  2013       Impact factor: 2.083

10.  Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.

Authors:  Joshua A Roth; Mark E Bensink; Paul V O'Donnell; Ephraim J Fuchs; Mary Eapen; Scott D Ramsey
Journal:  J Comp Eff Res       Date:  2014-03       Impact factor: 1.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.